Literature DB >> 12385855

The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer.

V H W M Jongen1, A V Sluijmer, M J Heineman.   

Abstract

Postmenopausal estrogens originate from the peripheral conversion of androgens, which are produced by the adrenal glands and the ovaries. Estrogens are considered to contribute to the neoplastic development of endometrium. Hyperplasia of ovarian stroma is associated with an increased androgen production by the ovaries and with the development of endometrial pathology. We hypothesize that, in cases of endometrial pathology, an increased production of aromatizable androgens by postmenopausal ovaries will lead to elevated prehormone availability for estrogen formation in utero. Following the conversion of ovarian androgens, a reaction catalyzed by the cytochrome p450 aromatase, estrogens may function as a local mitogenic factor eventually leading to the development of endometrial cancer. We consider the local availability of androgens and the local activity of aromatase relevant for this process. If this hypothesis proves to be right it may give rise to the introduction of aromatase inhibitors in treatment strategies of hormone dependent endometrial malignancies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385855     DOI: 10.1016/s0378-5122(02)00140-8

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  9 in total

1.  The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women.

Authors:  Kim N Danforth; A Heather Eliassen; Shelley S Tworoger; Stacey A Missmer; Robert L Barbieri; Bernard A Rosner; Graham A Colditz; Susan E Hankinson
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

2.  Effect of ovarian aging on androgen biosynthesis in a cynomolgus macaque model.

Authors:  K F Ethun; C E Wood; C R Parker; J R Kaplan; H Chen; S E Appt
Journal:  Climacteric       Date:  2011-08-24       Impact factor: 3.005

3.  Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome.

Authors:  A Burelli; R Cionini; E Rinaldi; E Benelli; E Fiore; D Canale; W Bencivelli; C Nencetti; A Pinchera; E Pucci
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

4.  Ovarian volumes among women with endometrial carcinoma: associations with risk factors and serum hormones.

Authors:  Mark E Sherman; M Patricia Madigan; James V Lacey; Montserrat Garcia-Closas; Nancy Potischman; Joseph D Carreon; Patricia Hartge; Louise A Brinton
Journal:  Gynecol Oncol       Date:  2007-08-27       Impact factor: 5.482

Review 5.  Gynaecological cancers and leptin: A focus on the endometrium and ovary.

Authors:  A Ray; J Fornsaglio; S Dogan; S Hedau; D Naik; A De
Journal:  Facts Views Vis Obgyn       Date:  2018-03

6.  A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xing-Wei Liang; Zhen-Bo Wang; Zhao-Yi Wang; Jie Qiao; Heide Schatten; Qing-Yuan Sun
Journal:  Reprod Biol Endocrinol       Date:  2009-09-24       Impact factor: 5.211

7.  FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer.

Authors:  Meiting Qiu; Wei Bao; Jingyun Wang; Tingting Yang; Xiaoying He; Yun Liao; Xiaoping Wan
Journal:  BMC Cancer       Date:  2014-02-11       Impact factor: 4.430

Review 8.  Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.

Authors:  Olena Bilyk; Mackenzie Coatham; Michael Jewer; Lynne-Marie Postovit
Journal:  Front Oncol       Date:  2017-07-05       Impact factor: 6.244

9.  Ovarian volume assessment in relation to histologic findings and sex hormone levels in women with postmenopausal bleeding and thickened endometrium.

Authors:  Amr K Elfayomy; Shereen A El Tarhouny
Journal:  Ann Saudi Med       Date:  2012 Nov-Dec       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.